We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

FUJIREBIO

Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App





Fujirebio Showcases Range of Novel Testing Solutions

By LabMedica International staff writers
Posted on 14 Nov 2023
Print article
Image: The LUMIPULSE G series of instruments was on display at MEDICA 2023 (Photo courtesy of Fujirebio)
Image: The LUMIPULSE G series of instruments was on display at MEDICA 2023 (Photo courtesy of Fujirebio)

Fujirebio (Tokyo, Japan) is showcasing its LUMIPULSE G series of chemiluminescent enzyme immunoassay (CLEIA) analyzers and kits for fully automated testing at MEDICA 2023. The LUMIPULSE G series includes the LUMIPULSE G1200 fully automated immunoassay instrument which uses a unique mono test cartridge concept. It has a true throughput of 120 tests per hour and provides outstanding flexibility and easy handling in hospitals and clinical laboratories.

Fujirebio is also highlighting the latest member of the LUMIPULSE G series, the LUMIPULSE G600II which is a compact and robust benchtop analyzer with a constant throughput of 60 tests per hour. The system uses a unique mono test cartridge concept (the same cartridge concept as the mid-sized LUMIPULSE G1200 analyzer) and offers outstanding flexibility and easy handling to hospitals and clinical laboratories. The easy-to-use analyzer provides a perfect fit in laboratories aiming for personalized workflow solutions without compromising testing quality. Fujirebio offers a number of kits for fully automated testing on the LUMIPULSE G series of CLEIA analyzers.

This includes Lumipulse G 25-OH Vitamin D is an immunoreaction cartridge for in vitro diagnostic (IVD) use for the quantitative determination of 25-hydroxyvitamin D (25-OH-D) in human serum or plasma to be used in the assessment of Vitamin D sufficiency. Fujirebio is highlighting the Lumipulse G Aldosterone immunoreaction cartridges for the quantitative measurement of aldosterone in human serum, plasma, or urine. Also being showcased at MEDICA 2023 is the Lumipulse G B•R•A•H•M•S PCT immunoreaction cartridges for IVD use with a two-step sandwich immunoassay method on the LUMIPULSE G system for the quantitative determination of procalcitonin (PCT) in human serum and plasma.

Related Links:
Fujirebio 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Amoebiasis Test
ELI.H.A Amoeba
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: The advanced molecular test is designed to improve diagnosis of a genetic form of COPD (Photo courtesy of National Jewish Health)

Groundbreaking Molecular Diagnostic Test Accurately Diagnoses Major Genetic Cause of COPD

Chronic obstructive pulmonary disease (COPD) and Alpha-1 Antitrypsin Deficiency (AATD) are both conditions that can cause breathing difficulties, but they differ in their origins and inheritance.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.